Carrick Therapeutics

Executive Summary

Carrick Therapeutics is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland, focused on developing innovative small molecule therapies for oncology. Founded in 2015, the company has built a pipeline of best-in-class and first-in-class candidates aimed at improving patient outcomes in difficult-to-treat cancers. Carrick's lead programs are in Phase 2 development, targeting key oncogenic pathways with novel mechanisms of action. The company leverages its deep expertise in medicinal chemistry and translational biology to advance therapies that have the potential to overcome resistance and provide meaningful clinical benefit. With a strong scientific foundation and a focused pipeline, Carrick Therapeutics is positioned to deliver value through disciplined clinical execution and strategic partnerships.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead program35% success
• H1 2027Initiation of Phase 3 trial for lead candidate60% success
• 2026Potential strategic partnership or licensing deal50% success